Cheng Liu

Cheng Liu

Company: Eureka Therapeutics, Inc.

Job title: Founder & CEO


Overcoming Solid Tumor Challenges with ARTEMIS® Antibody Redirected T-Cell Therapy 2:45 pm

Designing ARTEMIS® Antibody TCR (AbTCR) T-cells to address the major hurdles in treating solid tumor Infiltrating into solid tumor under immunosuppressive microenvironment Targeting Alpha-fetoprotein (AFP) and Glypican 3 (GPC3) in advanced hepatocellular carcinoma (HCC) Demonstrating superior safety and efficacy profile of ARTEMIS® T-cellsRead more

day: Bootcamp Day

Keynote Panel Discussion – Driving Clinical Success in Solid Tumor Settings 10:00 am

What is the optimal cell type to tackle the solid tumor microenvironment What solid tumors should the field be targeting first, considering myeloid compartments and heterogeneity? Address acquired versus inherent resistance to immunotherapy Discuss how different modalities induce epitope spreading and the potential of this to overcome heterogeneityRead more

day: Day One

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.